Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 1

Status

Completed 3Not yet recruiting 1

Sponsor Class

OTHER 4NETWORK 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Gastrointestinal 2Other hematologic neoplasm 1Other 1Genitourinary 1

Conditions

Breast Neoplasms 3Peripheral Nervous System Diseases 1Pain 1CIPN 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 265Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 145Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Duloxetine Hydrochloride × Breast × Clear all
NCT06711978 2024-12-02

Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors

Pusan National University Yangsan Hospital

Phase NA Not yet recruiting
66 enrolled
BreastOther

CIPN

NCT04732455 2022-07-11

TIPN

Alexandria University

Phase NA Completed
60 enrolled
Breast

Breast Neoplasms, Peripheral Nervous System Diseases

NCT01912612 2020-08-06

Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain

University of Michigan Rogel Cancer Center

Phase 2 Completed
82 enrolled 26 charts
Breast

Breast Neoplasms, Pain

NCT01028352 2013-08-08

Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain

University of Michigan Rogel Cancer Center

Phase NA Completed
35 enrolled 6 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡